Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition.
暂无分享,去创建一个
[1] J. Cohn,et al. Prognostic Significance of Serial Changes in Left Ventricular Ejection Fraction in Patients With Congestive Heart Failure , 1993, Circulation.
[2] F. Tristani,et al. Ejection Fraction, Peak Exercise Oxygen Consumption, Cardiothoracic Ratio, Ventricular Arrhythmias, and Plasma Norepinephrine as Determinants of Prognosis in Heart Failure , 1993, Circulation.
[3] M. Daemen,et al. Angiotensin II Receptor Blockade After Myocardial Infarction in Rats: Effects on Hemodynamics, Myocardial DNA Synthesis, and Interstitial Collagen Content , 1992, Journal of cardiovascular pharmacology.
[4] J. Cohn,et al. Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure Relations to Survival and the Effects of Therapy in V‐HeFT II , 1993, Circulation.
[5] F. Tristani,et al. Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .
[6] J. Cohn,et al. Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. , 1994, Journal of the American College of Cardiology.
[7] J. Cohn. Vasodilator Therapy for Heart Failure: The Influence of Impedance on Left Ventricular Performance , 1973, Circulation.
[8] B. Magnani,et al. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction , 1995 .
[9] G. Murray,et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .
[10] J. Cohn,et al. Role of the Renin-Angiotensin System in the Systemic Vasoconstriction of Chronic Congestive Heart Failure , 1978, Circulation.
[11] W. Linz,et al. A specific B2‐bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril , 1992, British journal of pharmacology.
[12] J. A. Snow,et al. Chronic vasodilator therapy in the management of cardiogenic shock and intractable left ventricular failure. , 1974, Annals of internal medicine.
[13] J. Ross,et al. Oxygen consumption of the heart. Newer concepts of its multifactoral determination. , 1968, The American journal of cardiology.
[14] M. Quiñones,et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. , 1995, Circulation.
[15] B. Jugdutt,et al. Effect of long-term captopril therapy on left ventricular remodeling and function during healing of canine myocardial infarction. , 1992, Journal of the American College of Cardiology.
[16] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[17] G. Lamas,et al. Quantitative Two-Dimensional Echocardiographic Measurements are Major Predictors of Adverse Cardiovascular Events After Acute Myocardial Infarction: The Protective Effect of Captopril , 1994, Circulation.
[18] G. Lamas,et al. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. , 1988, The New England journal of medicine.
[19] K. Uğurbil,et al. Myocardial bioenergetic abnormalities in a canine model of left ventricular dysfunction. , 1994, Journal of the American College of Cardiology.
[20] K. Swedberg,et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) , 1992, The New England journal of medicine.
[21] F. Tristani,et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.
[22] S. Yusuf,et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. , 1992, Circulation.
[23] J. Cohn,et al. Long-term oral nitrate therapy prevents chronic ventricular remodeling in the dog. , 1993, Journal of the American College of Cardiology.
[24] O. Carretero,et al. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. , 1993, Circulation research.
[25] T. Parrish,et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. , 1995, Circulation.
[26] J. Cohn,et al. Myocardial damage after repetitive direct current shock in the dog: correlation between left ventricular end-diastolic pressure and extent of myocardial necrosis. , 1978, The Journal of laboratory and clinical medicine.
[27] W. Linz,et al. Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats. , 1991, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[28] J. Cohn,et al. Relative Effects of α1‐Adrenoceptor Blockade, Converting Enzyme Inhibitor Therapy, and Angiotensin II Subtype 1 Receptor Blockade on Ventricular Remodeling in the Dog , 1994, Circulation.
[29] J. Cohn,et al. Hemodynamic, left ventricular structural and hormonal changes after discrete myocardial damage in the dog. , 1992, Journal of the American College of Cardiology.